NCT06181266View on ClinicalTrials.gov

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

July 30, 2027

Conditions
NMIBCHigh Risk NMIBCNon Muscle Invasive Bladder Cancer
Interventions
DRUG

ZH9

ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.

Trial Locations (4)

27710

Duke Health-Duke Cancer Center, Durham

29572

Carolina Urologic Research Center, LLC, Myrtle Beach

78229

Urology San Antonio Medical Center, San Antonio

93301

Michael G. Oefelein Clinical Trials, Bakersfield

All Listed Sponsors
lead

Prokarium Ltd

INDUSTRY